Efficacy of omalizumab in eosinophilic chronic rhinosinusitis patients with asthma

Tajiri, Tomoko; Matsumoto, Hisako; Hiraumi, Harukazu; Ikeda, Hiroki; Morita, Kyohei; Izuhara, Kenji; Ono, Junya; Ohta, Shoichiro; Ito, Isao; Oguma, Tsuyoshi; Nakaji, Hitoshi; Inoue, Hideki; Iwata, Toshiyuki; Nagasaki, Tadao; Kanemitsu, Yoshihiro; Ito, Juichi; Niimi, Akio; Mishima, Michiaki

doi:10.1016/j.anai.2013.01.024

Cited by 51 publications

(29 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the same study, the researchers found a significant reduction in induced sputum eosinophilia from 6% to 2% ( p<0.001) and a significant increase in FEV1 after omalizumab treatment, with both changes significantly correlating with changes in WA% [65]. Similar findings were later reported by TAJIRI et al [71].…”

Section: Omalizumab and Airway Inflammationsupporting

confidence: 77%

Anti-IgE treatment, airway inflammation and remodelling in severe allergic asthma: current knowledge and future perspectives

et al. 2015

View full text Add to dashboard Cite

Asthma is a disorder of the airways involving various inflammatory cells and mediators and characterised by bronchial hyperresponsiveness, chronic inflammation and structural alterations in the airways, also known as remodelling. IgE is an important mediator of allergic reactions and has a central role in allergic asthma pathophysiology, as it is implicated in both the early and late phase allergic response. Moreover, clinical and mechanistic evidence has lately emerged, implicating IgE in the development of airway remodelling. The use of monoclonal antibodies targeting IgE, such as omalizumab, has proven very effective in improving respiratory symptoms and quality of life, while reducing asthma exacerbations, emergency room visits and the use of systemic corticosteroids in allergic severe asthma. These effects are believed to be mainly mediated by omalizumab's inhibitory effect on the initiation and further propagation of the allergic inflammation cascade. However, there is evidence to suggest that anti-IgE treatment remains effective long after it has been discontinued. In part, these findings could be attributed to the possible ameliorating effects of anti-IgE treatment on airway remodelling. In this review, we discuss recent findings supporting the notion that anti-IgE treatment modulates the complex immune responses that manifest clinically as asthma and ameliorates airway remodelling changes often observed in allergic severe asthma phenotypes. @ERSpublications Anti-IgE treatment suppresses the inflammatory airway response and markers of remodelling in allergic asthma http://ow.ly/Som4i

show abstract

Section: Omalizumab and Airway Inflammationsupporting

confidence: 77%

Anti-IgE treatment, airway inflammation and remodelling in severe allergic asthma: current knowledge and future perspectives

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Treatment is very costly, and it is currently only FDA approved for patient with moderate to severe or severe allergic asthma and signifi cantly elevated IgE. A small prospective uncontrolled trial looked at the effi cacy of 16 weeks of omalizumab treatment in patients with eosinophilic chronic rhinosinusitis and severe atopic asthma [ 58 ]. This study showed improvement in rhinologic symptoms and sinus CT score in addition to improved asthma control.…”

Section: Anti-ige Therapymentioning

confidence: 92%

Overview of the Medical Management of Chronic Rhinosinusitis

Crosby

Kennedy

2015

Practical Medical and Surgical Management of Chronic Rhinosinusitis

View full text Add to dashboard Cite

“…There were significant decreases in NP size and in intranasal corticosteroid use, and none of the patients needed additional surgery during the relatively long follow-up after surgery; however, there was no comparison group in this study. Tajiri et al 44 prospectively evaluated the efficacy of omalizumab in 6 patients with NP and patients with severe allergic asthma and mean AE SD total IgE levels of 332 AE 209 IU/mL. After 16 weeks of therapy, the Lund-Mackay radiologic sinus score (primary end point) was significantly lower and this was correlated with changes in serum levels of periostin, a marker for eosinophilic airway inflammation.…”

Section: Nasal Polyposismentioning

confidence: 96%